• Remi A Kessler, Tomas Garzon-Muvdi, Wuyang Yang, Jon Weingart, Alessandro Olivi, Judy Huang, Henry Brem, and Michael Lim.
• Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
• World Neurosurg. 2017 May 1; 101: 47-56.

BackgroundAtypical (World Health Organization grade II) and anaplastic (World Health Organization grade III) meningiomas are rare, accounting for less than 5% of all meningiomas. Histologic grading has a significant impact on prognosis, risk of recurrence, and the need for adjuvant radiation or chemotherapy. Extracranial metastases are even more infrequent and occur in 0.1% of all cases.MethodsRetrospective chart review of 168 patients with diagnosis of WHO grade II and III meningiomas was performed. Six patients with histologically confirmed metastatic disease were identified.ResultsWe discuss the clinical, radiologic, and histopathologic clinical course of 6 patients with metastasis to the lung, liver, and spine from all patients with atypical or anaplastic meningioma treated at Johns Hopkins Hospital from 1993 to 2014.ConclusionsWe reviewed the literature pertaining to this phenomenon and subsequently assessed the clinical benefits of adjuvant chemotherapeutic agents in patients with meningioma with metastatic disease.Copyright © 2017 Elsevier Inc. All rights reserved.

32 keywords...

hide…